ABSTRACT
Introduction Epithelial cell-derived cytokines IL-25, IL-33 and TSLP initiate type 2 inflammation in allergic diseases. However, the signaling pathway regulating these cytokines expression remains elusive. We examined the role of epithelial microRNAs in the expression of IL-25, IL-33 and TSLP in asthma.
Methods Differentially expressed epithelial microRNAs between type 2-low and type 2-high asthma patients were identified using microarray. The expression of microRNA (miR)-206, its target CD39, CD39’s substrate ATP, and IL-25, IL-33, TSLP were measured in epithelial brushings and bronchoalveolar lavage fluid from both asthma subsets and healthy controls. The links between these measurements were functionally validated in vitro and in vivo.
Results MiR-206 was the most highly expressed microRNA in type 2-high asthma relative to type 2-low asthma, but was downregulated in both asthma subsets compared with healthy controls. CD39, an ecto-nucleotidase degrading ATP, was a target of miR-206 and upregulated in asthma. Allergen-induced acute extracellular ATP accumulation led to miR-206 downregulation and CD39 upregulation in human bronchial epithelial cells, forming a feedback loop to eliminate excessive ATP. Airway ATP levels strongly correlated with elevated IL-25 and TSLP expression in type 2-high asthma patients. Intriguingly, airway miR-206 antagonism increased Cd39 expression, reduced ATP accumulation, suppressed Il-25, Il-33, Tslp expression and group 2 innate lymphoid cells expansion, and alleviated type 2 inflammation in a mouse model of asthma. However, airway miR-206 overexpression had opposite effects.
Conclusion Together, epithelial miR-206 upregulates airway IL-25, TSLP expression via targeting CD39-extracellular ATP axis, which represents a novel therapeutic target in type 2-high asthma.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (grants 91742108, 81670019, 81800026, 81600023), National Key Research and Development Program of China (2016YFC1304400), and Hubei Province Natural Science Foundation (grant 2017CFA016).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human and mouse studies were approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available. The array data are available at GEO (http://www.ncbi.nlm.nih.gov/geo/, accession number GSE142237).
